Note: Ingredients listed on restricted chemical lists
EC/CAS
50-99-7
Name of the chemical
Glucose C6H12O6
Concentration
N/A
EC/CAS
69-65-8
Name of the chemical
D-mannitol C6H14O6
Concentration
N/A
EC/CAS
200-075-1
Name of the chemical
Glucose C6H12O6
Concentration
N/A
EC/CAS
200-711-8
Name of the chemical
D-mannitol C6H14O6
Concentration
N/A
General Information
Revision date
2007-01-17
Product name
Reomax Ampoules
Emergency telephone
(24 hours) 1-800-424-9300
Icons in SDS
Company Information
company name
Pfizer Inc
GHS Information
Signal word
WARNING
Section 2
SECTION 2: Hazards identification
Appearance: Powder for reconstitution plus sterile diluent
Signal word
WARNING
Hazard statements
Harmful if swallowed.
Additional information
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver (based on components) . Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include loss of appetite (anorexia), abdominal pain, changes in electrolytes, inability to swallow (dysphagia), nausea, vomiting, thirst, diarrhea. Clinical use has resulted in liver effects. Symptoms may include jaundice, liver function test abnormalities, and hepatitis. May cause adverse effects on the kidney. Other less common effects include allergic reaction, effects on hearing, vision. Drowsiness, fatigue, or headache are also possible. EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
